Open an account

Nkarta

NKTX · NASDAQ

$1.74−$0.01 (−0.57%)TodayMarket closed ·
Prev close $1.75

About NKTX

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 108 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

Employees
108
Headquarters
South San Francisco, California
Listed
Jul 10, 2020
Sector
Health Care
Industry
Biotechnology
Website
nkartatx.com

NKTX key statistics

Market cap
124.63M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
765.90K
Volume
1.14M
Open price
$1.76
High today
$1.82
Low today
$1.74
52 Week high
$3.72
52 Week low
$1.70

Nkarta (NKTX) at a glance

Nkarta (NKTX) last traded at $1.74, with a market cap of 124.63M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.74 and $1.82. The current price is 0.0% above the day's low and 4.4% below its high.

Volume so far is 1.14M shares, above the average of 765.90K shares a day.

Over the past year Nkarta has ranged from $1.70 to $3.72, and now sits 2% of the way up that range.

Nkarta met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.54 per share against an estimate of -$0.3835.

The average analyst price target is $11.05, 535.1% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $11.05
Low
$9.09
Now
$1.74
High
$14.70

NKTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 9.5% on average.

  1. Q3 FY24: reported -$0.39 per share against an estimate of -$0.3723
  2. Q4 FY24: reported -$0.35 per share against an estimate of -$0.4211
  3. Q1 FY25: reported -$0.43 per share against an estimate of -$0.4488
  4. Q2 FY25: reported -$0.31 per share against an estimate of -$0.3621
  5. Q3 FY25: reported -$0.29 per share against an estimate of -$0.3196
  6. Q4 FY25: reported -$0.37 per share against an estimate of -$0.3244
  7. Q1 FY26: reported -$0.37 per share against an estimate of -$0.38
  8. Q2 FY26: reported -$0.54 per share against an estimate of -$0.3835

NKTX news

  • Press releasePRNewswire

    A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

  • Press releaseGlobe Newswire

    After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

  • Press releaseGlobe Newswire

    Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

  • Press releasePRNewswire

    The $13 Million Company Teaching the Immune System to Hunt Cancer

  • Press releasePRNewswire

    Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

  • Vandana Singh

    Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

Similar companies

Companies in the same industry as Nkarta

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.